Braun Bostich & Associates Inc. Biogen Inc. Transaction History

Braun Bostich & Associates Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$236.26 - $355.63 $42,526 - $64,013	-180 Closed	0 $0
Q3 2020 Oct 09, 2020	SELL	$264.77 - $305.71 $81,019 - $93,547	-306 Reduced 62.96%	180 $51,000
Q4 2019 Jan 29, 2020	BUY	$220.06 - $304.07 $106,949 - $147,778	486 New	486 $143,000
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $197,435 - $221,443	-908 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $166,221 - $183,223	-758 Reduced 45.5%	908 $212,000
Q1 2019 May 09, 2019	SELL	$216.71 - $338.96 $90,584 - $141,685	-418 Reduced 20.06%	1,666 $394,000
Q4 2018 Feb 08, 2019	BUY	$278.5 - $352.75 $557 - $705	2 Added 0.1%	2,084 $627,000
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $12,327 - $16,120	42 Added 2.06%	2,082 $736,000
Q2 2018 Aug 10, 2018	SELL	$257.52 - $306.91 $5,150 - $6,138	-20 Reduced 0.97%	2,040 $592,000
Q1 2018 May 16, 2018	BUY	$260.13 - $367.91 $35,377 - $50,035	136 Added 7.07%	2,060 $0
Q4 2017 May 21, 2018	BUY	$307.64 - $344.58 $591,899 - $662,971	1,924	1,924 $613,000

990

131M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Braun Bostich & Associates Inc., based on Form 13F filings with the SEC.

Stay updated on Braun Bostich & Associates Inc. with notifications on news.